GAT100
GAT100 is a negative allosteric modulator and covalent allosteric probe for cannabinoid receptor type 1 (CB1R). GAT100 acts as a positive allosteric modulator for orthosteric agonist CP55,940 binding to regulate the CB1R signaling pathway. GAT100 reduces the potency and efficacy of orthosteric CB1R agonists in terms of β-arrestin 1 recruitment, phosphorylation of PLCβ3 and ERK1/2, cAMP accumulation, and CB1R internalization. GAT100 is applicable to the research of psychobehavioral and somatic diseases.
For research use only. We do not sell to patients.
- CAS No.: 1663564-42-8
- Formula: C25H28N4OS
- Molecular Weight:432.59
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
19.6 nM
Compound: 20; GAT100
|
Positive allosteric modulator activity at human CB1R expressed in CHO cells assessed as enhanced binding of [3H]CP55,940 after 60 mins by liquid scintillation spectrometric analysis
Positive allosteric modulator activity at human CB1R expressed in CHO cells assessed as enhanced binding of [3H]CP55,940 after 60 mins by liquid scintillation spectrometric analysis
|
[PMID: 26529344] |
| CHO-K1 | EC50 |
174 nM
Compound: 20; GAT100
|
Negative allosteric modulator activity at human CB1R expressed in CHO-K1 cells assessed as effect on CP55,940-induced inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins followed by CP55,940 addition measured for 30 mins by HitHunte
Negative allosteric modulator activity at human CB1R expressed in CHO-K1 cells assessed as effect on CP55,940-induced inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins followed by CP55,940 addition measured for 30 mins by HitHunte
|
[PMID: 26529344] |
| CHO-K1 | EC50 |
2.09 nM
Compound: 20; GAT100
|
Negative allosteric modulator activity at human CB1R expressed in CHO-K1 cells assessed as inhibition of CP55,940-induced beta-arrestin recruitment preincubated for 30 mins followed by CP55,940 addition measured for 90 mins by PathHunter assay
Negative allosteric modulator activity at human CB1R expressed in CHO-K1 cells assessed as inhibition of CP55,940-induced beta-arrestin recruitment preincubated for 30 mins followed by CP55,940 addition measured for 90 mins by PathHunter assay
|
[PMID: 26529344] |
In Vitro
GAT100 (Compound 20) (30 min preincubation, 90 min co-incubation with CP55,940) potently inhibits CP55,940-dependent β-arrestin recruitment and cAMP accumulation in CHO-K1 hCB1R cells, with EC50 values of 2.09 nM and 174 nM, respectively[1].
GAT100 (treated at 37 °C for 60 minutes) acts as a positive allosteric modulator of [3H]CP55,940 binding to CHO hCB1R membranes, with an EC50 of 19.6 nM[1].
GAT100 (500 nM; 0-120 min) covalently labels hCB1R in the cell membrane of HEK293 cells in a time-dependent manner and forms a covalent bond with hCB1R[1].
GAT100 (30 min) potently inhibits CB1-mediated β-arrestin1 recruitment, PLCβ3 phosphorylation, and ERK1/2 phosphorylation in HEK293A, Neuro2a, and STHdhQ7/Q7 cells[2].
GAT100 (1-10000 nM; 4 h) potently inhibits CB1-mediated, forskolin-stimulated cAMP accumulation in HEK-CRE cells[2].
GAT100 (1 μM; 0.5-20 h) rapidly reverses CP55,940-induced CB1 endocytosis in STHdhQ7/Q7 cells, and it restores plasma membrane CB1 levels more rapidly than the reference allosteric modulator[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEK293A cells transiently transfected with hCB1-GFP2, Neuro2a cells endogenously expressing CB1, STHdhQ7/Q7 cells endogenously expressing CB1
-
Concentration:1-10000 nM; 500 nM (co-treated with 2-AG, AEA, or CP55,940)
-
Incubation Time:10 min
-
Result:Inhibited PLCβ3 phosphorylation in HEK293A cells with IC50 values of 56.1 nM (44.0-62.6 nM, with 2-AG), 50.2 nM (23.9-65.3 nM, with AEA), 76.6 nM (60.8-103 nM, with CP55,940), and Eₘₐₓ values of 0.39, 0.36, 0.39, respectively.
Inhibited PLCβ3 phosphorylation in Neuro2a cells with IC50 values of 50.1 nM (33.4-79.2 nM, with 2-AG), 60.3 nM (28.1-131 nM, with AEA), 49.0 nM (25.2-93.4 nM, with CP55,940), and Eₘₐₓ values of 0.34, 0.37, 0.39, respectively.
Inhibited PLCβ3 phosphorylation in STHdhQ7/Q7 cells with IC50 values of 52.7 nM (39.8-63.1 nM, with 2-AG), 57.4 nM (35.9-66.1 nM, with AEA), 71.0 nM (67.2-79.7 nM, with CP55,940), and Eₘₐₓ values of 0.37, 0.37, 0.38, respectively.
Showed no effect on basal PLCβ3 phosphorylation when tested alone (1 nM to 10 μM) in any cell type.\nInhibited ERK1/2 phosphorylation in HEK293A cells with IC50 values of 69.4 nM (50.2-76.5 nM, with 2-AG), 56.6 nM (29.3-71.6 nM, with AEA), 84.1 nM (78.3-96.1 nM, with CP55,940), and Eₘₐₓ values of 0.33, 0.31, 0.29, respectively.
Inhibited ERK1/2 phosphorylation in Neuro2a cells with IC50 values of 57.5 nM (29.1-112 nM, with 2-AG), 57.5 nM (32.9-72.1 nM, with AEA), 47.9 nM (24.4-94.8 nM, with CP55,940), and Eₘₐₓ values of 0.31, 0.28, 0.33, respectively.
Inhibited ERK1/2 phosphorylation in STHdhQ7/Q7 cells with IC50 values of 57.9 nM (28.4-75.1 nM, with 2-AG), 51.3 nM (19.6-136 nM, with AEA), 52.3 nM (21.8-74.2 nM, with CP55,940), and Eₘₐₓ values of 0.37, 0.32, 0.34, respectively.
Showed no effect on basal ERK1/2 phosphorylation when tested alone (1 nM to 10 μM) in any cell type.
-
Cell Line:STHdhQ7/Q7 cells endogenously expressing CB1
-
Concentration:1 μM (co-treated with 500 nM CP55,940)
-
Incubation Time:0.5 h, 1 h, 5 h, 10 h, 15 h, 20 h
-
Result:Reversed CP55,940-induced CB1 internalization, increasing the fraction of CB1 at the plasma membrane to ~0.6 by 0.5 h.
Exhibited a more rapid effect than Org27569 or PSNCBAM-1.
Chemical Information
-
CAS No. 1663564-42-8
-
Molecular Weight 432.59
-
Formula C25H28N4OS
-
SMILES
O=C(NCCC1=CC=C(C=C1)N2CCCCC2)C=3NC=4C=CC(N=C=S)=CC4C3CC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
[1]. Kulkarni PM, et al. Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). J Med Chem. 2016;59(1):44-60. [Content Brief]
[2]. Laprairie RB, et al. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe. ACS Chem Neurosci. 2016;7(6):776-798. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)